Breaking News

Moderna outbid with an effective vaccine “at 94.5%”

Just a week after the Pfizer laboratory, the American biotechnology company announced Monday that it had developed a formula that drastically reduces the risk of contracting covid-19.

Just a week after the Pfizer laboratory, the American biotechnology company announced Monday that it had developed a formula that drastically reduces the risk of contracting covid-19.

(ASdN with AFP) – The vaccine race continues. A week after the announcement of a 90% effective serum from the Pfizer laboratory, the American biotechnology company Moderna announced on Monday that it had developed a vaccine against covid-19 effective “at 94.5%” to reduce the risk of contracting the disease. In this case, specifies the laboratory, 90 participants in the placebo group caught covid-19, against five in the group vaccinated during the clinical trial.

The Moderna vaccine, like the one from Pfizer, is based on the technique known as messenger RNA, which is the molecule that tells our cells what to make.

$ 145 million in shares

By developing effective formulas against the virus in record time, the pharmaceutical giants hope to receive their share of the pie. The same day the American company Pfizer announced the results of its preliminary data, its managing director Albert Bourla sold $ 5.6 million worth of securities. The boss of Novavax, for his part, sold $ 4.2 million in shares on August 18, just over a month after the announcement of public funding of $ 1.6 billion.

For their part, several Moderna officials have sold more than a hundred million dollars in shares in recent months, AFP said on Monday. The company has not launched any product on the market since its inception in 2010, but the US government has pledged up to $ 2.5 billion if its vaccine is validated. The title went from 19 dollars at the beginning of the year to 90 dollars now.

The taxpayer advocacy organization Accountable US calculated that between the start of the US operation to coordinate vaccine development on May 15 and August 31, executives of five drug companies had collected more than $ 145 million. dollars by selling their shares

Record time

However, no vaccine has yet received approval for large-scale commercial distribution. But Chinese authorities have given the green light for emergency use for some of these vaccines. According to the World Health Organization (WHO), ten vaccine clinical trials are currently in phase 3 worldwide, including those of the American biotech Moderna, several Chinese state laboratories and the British AstraZeneca, in collaboration with the university from Oxford.

The development of the latter would, however, constitute a speed record for the development of a vaccine, less than a year after the appearance of the coronavirus in China. These precious serums also give hope for a return to normal life.

As a reminder, the virus has claimed more than 1.3 million victims around the world. More than 54.4 million cases of the new coronavirus have been detected since December, according to a report established from official sources.


Tags

Related Articles

Back to top button
Close
Close